Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16369967 | 0.90 | L3MBTL1 (0.55) | L3MBTL1CTSBNPSR1PPARAALDH1A1 | |
| SCHEMBL16369968 | 0.90 | L3MBTL1 (0.55) | L3MBTL1CTSBNPSR1PPARAALDH1A1 | |
| SCHEMBL16369984 | 0.87 | L3MBTL1 (0.52) | L3MBTL1CTSBNPSR1PPARAALDH1A1 | |
| SCHEMBL16369983 | 0.87 | L3MBTL1 (0.52) | L3MBTL1CTSBNPSR1PPARAALDH1A1 | |
| SCHEMBL16993182 | 0.83 | L3MBTL1 (0.62) | L3MBTL1CTSBNPSR1PPARAALDH1A1 | |
| SCHEMBL22945722 | 0.82 | CTSB (0.59) | L3MBTL1CTSBALDH1A1LMNAHTT | |
| SCHEMBL25852154 | 0.81 | KMT2A (0.59) | L3MBTL1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL6987866 | 0.81 | L3MBTL1 (0.59) | L3MBTL1CTSBNPSR1PPARAALDH1A1 | |
| SCHEMBL8501723 | 0.81 | L3MBTL1 (0.59) | L3MBTL1CTSBNPSR1PPARAALDH1A1 | |
| SCHEMBL25291183 | 0.81 | L3MBTL1 (0.48) | L3MBTL1CTSBNPSR1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496053-B1 | Kappa-opioid receptor agonist comprising a 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-1496053-B1 | Kappa-opioid receptor agonist comprising a 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-06-20 | — | — | EP | disclosed |
| CN-1642929-B | Kappa-opioid receptor agonists containing 2-phenylbenzothiazoline derivatives | SANTEN PHARMACEUTICAL CO LTD | 2010-05-12 | — | — | CN | disclosed |
| CN-100522954-C | Kappa-opioid receptor agonist composed of 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| EP-2042173-A2 | Kappa-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-2042173-A2 | Kappa-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| US-7410987-B2 | Method for treating pain or pruritis by administering κ-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7410987-B2 | Method for treating pain or pruritis by administering κ-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7410987-B2 | Method for treating pain or pruritis by administering κ-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| CN-1911918-A | Kappa-opioid receptor agonist composed of 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO LTD (JP) | 2007-02-14 | — | — | CN | disclosed |
| US-7112598-B2 | κ opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-09-26 | — | — | US | disclosed |
| US-20060205796-A1 | Method for treating pain or pruritis by administering opinoid receptor agonist comprising 2-phenylbenzothiazoling derivative | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-09-14 | — | — | US | disclosed |
| CN-1642929-A | Kappa-opioid receptor agonists containing 2-phenylbenzothiazoline derivatives | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-07-20 | — | — | CN | disclosed |
| US-20050113430-A1 | Kappa-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1496053-A1 | KAPPA-OPIOID RECEPTOR AGONIST COMPRISING 2-PHENYLBENZOTHIAZOLINE DERIVATIVE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113430-A1 | Kappa-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | OPRK1, OPRD1, OPRL1 | L3MBTL1 2897/4885CTSB 2630/4885NPSR1 20/4885 |
| US-20060205796-A1 | Method for treating pain or pruritis by administering opinoid receptor agonist comprising 2-phenylbenzothiazoling derivative | OPRL1, OPRK1, OPRD1 | L3MBTL1 3310/4885CTSB 1738/4885NPSR1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.